Aptar reports first commercial use of Activ-Film in a dry powder inhaler

Aptar Active Material Science, part of Aptar, has reported the first commercial use of its Activ-Film technology in a capsule-based dry powder inhaler, extending a platform previously used in oral solid-dose drugs, implants and diagnostics. The material sits in a separate cavity within the aluminium blister, connected by a channel to the drug cavity, and is engineered to manage moisture, oxygen and VOCs without contacting the drug. Aptar declined to name the inhaler manufacturer, citing confidentiality.

Why this mattersExtends active packaging beyond solid-dose pharma into inhalation devices, opening a new application area for stability-control materials in drug delivery.

• Aptar Active Material Science reports the first commercial deployment of Activ-Film in a capsule-based dry powder inhaler.
• Activ-Film sits in a separate cavity in the aluminium blister, linked by a channel to the drug cavity to avoid direct contact.
• The technology is built on Aptar's 3-Phase Activ-Polymer platform and can manage moisture, oxygen and VOCs.
• Aptar opened a New Jersey manufacturing facility in 2025 dedicated to clinical packaging for oral solid-dose drugs and capsule-based DPI products.
• Aptar declined to identify the inhaler manufacturer using the technology, citing confidentiality agreements.
• The platform is already used in FDA-approved oral solid-dose drugs, implants and diagnostic products.

Relevant to you? Yes No